bay-63-2521 and Pulmonary-Disease--Chronic-Obstructive

Topics: Bosentan; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Insurance Coverage; Japan; Phenylpropionates; Prevalence; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Universal Health Insurance

Chronic obstructive pulmonary disease (COPD), which comprises the phenotypes of chronic bronchitis and emphysema, is often associated with pulmonary hypertension (PH). However, currently, no approved therapy exists for PH-COPD. Signalling of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) axis plays an important role in PH and COPD.We investigated the treatment effect of riociguat, which promotes the NO-cGMP pathway, in the mouse model of smoke-induced PH and emphysema in a curative approach, and retrospectively analysed the effect of riociguat treatment on PH in single patients with PH-COPD.In mice with established PH and emphysema (after 8 months of cigarette smoke exposure), riociguat treatment for another 3 months fully reversed PH. Moreover, histological hallmarks of emphysema were decreased. Microarray analysis revealed involvement of different signalling pathways,

Topics: Animals; Cyclic GMP; Disease Models, Animal; Humans; Hypertension, Pulmonary; Lung; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pyrazoles; Pyrimidines; Retrospective Studies; Signal Transduction; Soluble Guanylyl Cyclase; Translational Research, Biomedical

Topics: Acetamides; Anti-Bacterial Agents; Antiviral Agents; Bacterial Infections; Bacteriophages; Bronchodilator Agents; Drug Discovery; Enzyme Inhibitors; Feces; Humans; Influenza, Human; Isoquinolines; Lipopolysaccharides; Naphthalenes; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyrimidines; Pyrimidinones